cat no | io1020

ioGlutamatergic Neurons
PRKN R275W/R275W™

Human iPSC-derived Parkinson's disease model

ioGlutamatergic Neurons PRKN R275W/R275W are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered homozygous mutation in the PRKN gene encoding the Parkin protein. These cells offer a rapidly maturing, disease relevant and isogenic system for investigating the molecular and cellular significance of a homozygous R275W mutation in Parkinson’s disease.

Show more

Related disease model cells are available now with a heterozygous PRKN R275W mutation, and both can be used alongside their genetically matched control, ioGlutamatergic Neurons™.

Show less

Place your order

Vial size

Quantity

Price

per vial

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.

Add to basket

Click here for bulk request

Benchtop benefits

Make True Comparisons

Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the effect of homozygous expression of mutant Parkin protein on disease.

Scalable

With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.

Quick

The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Technical data

Technical data

Product information Supporting documentation Resources Related products

Highly characterised and defined

ioGlutamatergic Neurons PRKN R275W/R275W express neuron-specific markers comparably to the isogenic control

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins TUBB3 and MAP2 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PRKN R275W/R275W compared to the isogenic control. 100X magnification.

ioGlutamatergic Neurons PRKN R275W/R275W form structural neuronal networks by day 11

ioGlutamatergic Neurons PRKN R275W/R275W mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thawing; 100X magnification.

ioGlutamatergic Neurons PRKN R275W/R275W demonstrate gene expression of neuronal and glutamatergic-specific markers following reprogramming

Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/R275W and the isogenic control (WT) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data expressed relative to the parental hiPSC control (iPSC Control), normalised to HMBS). Data represents day 11 post-revival samples.

Disease-related PRKN is expressed in ioGlutamatergic Neurons PRKN R275W/R275W following reprogramming

Gene expression analysis demonstrates that ioGlutamatergic Neurons PRKN R275W/R275W and the isogenic control (WT) express the PRKN gene encoding the Parkin protein. Gene expression levels were assessed by RT-qPCR (data expressed relative to the parental hiPSC control (iPSC Control), normalised to HMBS). Data represents day 11 post-revival samples.

Cells arrive ready to plate

ioGlutamatergic Neurons PRKN R275W/R275W are delivered in a cryopreserved format and are programmed to rapidly mature upon revival in the recommended media. The protocol for the generation of these cells is a three-phase process: Induction, which is carried out at bit.bio (Phase 0), Stabilisation for 4 days (Phase 1), and Maintenance (Phase 2) during which the ioGlutamatergic Neurons PRKN R275W/R275W mature. Phases 1 and 2 after revival of cells are carried out by the customer.

 

Industry leading seeding density

ioGlutamatergic Neurons PRKN R275W/R275W cells are compatible with plates ranging from 6 to 384 wells.
The recommended seeding density is 30,000 cells/cm², compared to up to 500,000 cells/cm² for other similar products on the market.
This means scientists are able to do more with every vial and expand experimental design within budget without losing out on quality. Resulting in more experimental conditions, more repeats, and more confidence in the data.
One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plate. 

Product information

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 48, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male (skin fibroblast)

Vial size

Small: >1 x 10⁶ viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox cellular reprogramming

Recommended seeding density

30,000 cells/cm²

User storage

LN2 or -150°C

Format

Cryopreserved cells

Genetic modification

Homozygous R275W missense mutation in the PRKN gene

Applications

Parkinson's disease research
Drug discovery and development
Disease modelling

Product use

ioCells are for research use only

Supporting documentation

User Manual

Limited Use License & Statement of Use

Product resources

Webinar

Running Large-Scale CRISPR Screens in Human Neurons

Emmanouil Metzakopian | Vice President, Research and Development | bit.bio

Javier Conde-Vancells | Director Product Management | bit.bio

Watch now

Webinar

Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio

Watch now

Talk

Industrialising Cellular Reprogramming: Leveraging opti-ox™ Technology to Manufacture Human Cells with Unprecedented Consistency

Innovation showcase talk at ISSCR

Marius Wernig MD, PhD | Stanford 

Mark Kotter, MD, PhD | bit.bio

Watch now

Poster

Modelling neurodegeneration: Human isogenic system to study FTD & ALS

Dr Tony Oosterveen, et al.

bit.bio & Charles River Laboratories

2023

Download

Webinar

Rethinking Developmental Biology With Cellular Reprogramming

Mark Kotter | CEO and founder | bit.bio

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now

Talk

Precision Cellular Reprogramming for Scalable and Consistent Human Neurodegenerative Disease Models

Madeleine Garrett | Field Application Specialist | bit.bio

Watch now

Poster

Development and characterisation of a robust in vitro disease model to study tauopathies

Laila Ritsma et al.

Charles River Laboratories & bit.bio

2022

Download

Addressing current challenges of in vitro cell models 

Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.

Read the blog

Related products

 

ioDisease Model

ioGlutamatergic Neurons PRKN R275W/WT™ cat no. io1013

Order now

ioWild Type

ioGlutamatergic Neurons™ cat no. io1001

Order now

ioCRISPR-Ready

CRISPR-Ready ioGlutamatergic Neurons™ cat no. ioEA1090

Order now

ioDisease Model

ioGlutamatergic Neurons GBA null/WT™ cat no. io1007

Order now

ioDisease Model

ioGlutamatergic Neurons HTT 50CAG/WT™ cat no. ioEA1004

Order now

ioDisease Model

ioGlutamatergic Neurons MAPT N279K/WT™ cat no. io1009

Order now

ioDisease Model

ioGlutamatergic Neurons MAPT P301S/WT™ cat no. io1015

Order now

ioDisease Model

ioGlutamatergic Neurons TDP‑43 M337V/WT™ cat no. ioEA1006

Order now

ioDisease Model

ioGlutamatergic Neurons MAPT N279K/N279K™ cat no. io1014

Order now

ioDisease Model

ioGlutamatergic Neurons MAPT P301S/P301S™ cat no. io1018

Order now

ioDisease Model

ioGlutamatergic Neurons TDP‑43 M337V/M337V™ cat no. ioEA1005

Order now

Wild Type and Isogenic Disease Model cells: A true comparison.

Further your disease research by pairing our wild type cells with isogenic disease models.

Discover ioWild Type cells

Related pages

Discover ioCells Learn about our range of human iPSC-derived cells for research and drug discovery

Resources Explore our latest scientific insights, webinars, blogs and videos

Our platform Discover the cell identity coding platform that powers our ioCells